Home » Stocks » AIM ImmunoTech

AIM ImmunoTech, Inc. (AIM)

Stock Price: $2.99 USD 0.07 (2.40%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 97.55M
Revenue (ttm) 185,000
Net Income (ttm) -9.97M
Shares Out 32.62M
EPS (ttm) -5.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $2.99
Previous Close $2.92
Change ($) 0.07
Change (%) 2.40%
Day's Open 2.87
Day's Range 2.82 - 3.10
Day's Volume 6,559,349
52-Week Range 0.38 - 7.11

More Stats

Market Cap 97.55M
Enterprise Value 76.06M
Earnings Date (est) Aug 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 32.62M
Float 28.77M
EPS (basic) -0.63
EPS (diluted) -5.87
FCF / Share -0.61
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.40M
Short Ratio 0.48
Short % of Float 7.47%
Beta -0.81
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 527.28
PB Ratio 2.77
Revenue 185,000
Operating Income -12.84M
Net Income -9.97M
Free Cash Flow -10.73M
Net Cash 21.48M
Net Cash / Share 0.66
Gross Margin -407.03%
Operating Margin -6,941.62%
Profit Margin -5,390.80%
FCF Margin -5,800.54%
ROA -27.33%
ROE -51.11%
ROIC -52.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$6.17*
(106.35% upside)
Low
5.00
Current: $2.99
High
7.00
Target: 6.17
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue0.140.370.440.090.130.200.150.210.160.14
Revenue Growth-61.85%-16.02%375%-30.83%-32.49%31.33%-29.58%32.3%19.26%-
Gross Profit-0.75-0.52-0.75-1.02-1.47-1.05-1.08-1.78-0.88-1.21
Operating Income-12.44-11.27-11.42-12.18-16.65-19.10-17.17-20.34-14.30-16.39
Net Income-9.53-9.83-8.26-7.50-15.23-17.45-16.23-17.35-9.02-13.14
Shares Outstanding3.641.000.650.500.450.360.320.270.260.25
Earnings Per Share-2.62-9.77-12.76-14.96-33.88-48.83-52.80-63.36-36.96-52.80
Operating Cash Flow-9.07-10.64-7.94-7.38-16.05-13.96-16.90-13.14-10.10-11.89
Capital Expenditures-0.071.00-0.07-0.45-0.49-0.76-1.14-5.97-2.04-1.07
Free Cash Flow-9.14-9.64-8.01-7.83-16.54-14.73-18.04-19.10-12.13-12.95
Cash & Equivalents8.781.832.115.878.9116.1118.1943.9530.3635.61
Total Debt6.385.931.84--0.020.060.100.150.16
Net Cash / Debt2.40-4.100.275.878.9116.0918.1443.8530.2135.45
Assets20.2213.8514.2118.8722.8029.4431.8757.7043.5151.68
Liabilities7.318.675.503.382.434.442.5713.005.555.73
Book Value12.915.178.7015.5020.3725.0029.3044.7037.9745.95
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name AIM ImmunoTech, Inc.
Country United States
Employees 24
CEO Thomas Kenwood Equels

Stock Information

Ticker Symbol AIM
Stock Exchange NYSE American
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSEAMERICAN: AIM

Description

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has research agreement with the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd. to test its drug Ampligen as an adjuvant therapy for COVID-19, the new coronavirus infectious disease caused by SARS-CoV-2. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.